search
Back to results

Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS (AchALS)

Primary Purpose

Amyotrophic Lateral Sclerosis

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
endocannabinoid palmitoylethanolamide (PEA)
Riluzole
Sponsored by
University of Roma La Sapienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Amyotrophic Lateral Sclerosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of ALS according to the El-Escorial criteria;
  • Age> 18 years;
  • ALS Functional Rating Scale-Revised (ALSFRS- r) score> 20;
  • Forced Vital Capacity (FVC)> 30%;
  • Treatment with Riluzole.

Exclusion Criteria:

  • Other diseases motor neurons;
  • Experimental treatments in the previous three months;
  • Pregnant or breast-feeding;
  • Contraindications to the use of riluzole;
  • Patients undergoing tracheostomy, enteral or parenteral supply;
  • Severe psychiatric disorders.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Riluzole

    PEA plus Riluzole

    Arm Description

    Riluzole 50 mg twice daily in ALS patients

    Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients

    Outcomes

    Primary Outcome Measures

    Changes from baseline in pulmonary capacity of ALS patients at 6 months.
    Changes of the percentage of predicted forced vital capacity (FVC %) will be measured

    Secondary Outcome Measures

    Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.
    Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.
    Changes from baseline in muscle strength of ALS patients at 6 months.
    Changes of the Medical Research Council (MRC) scale score will be measured
    Changes from baseline in electrophysiological parameters of ALS patients at 6 months
    Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured

    Full Information

    First Posted
    December 22, 2015
    Last Updated
    January 1, 2016
    Sponsor
    University of Roma La Sapienza
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02645461
    Brief Title
    Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
    Acronym
    AchALS
    Official Title
    Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2014 (undefined)
    Primary Completion Date
    June 2015 (Actual)
    Study Completion Date
    December 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Roma La Sapienza

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration and progressive paralysis. Other studies have revealed defects in skeletal muscle even in absence of motor neuron anomalies, focusing on acetylcholine receptors (AChRs) and supporting the so-called "dying-back" hypothesis. Outcome of this study will be to understand if the endocannabinoid palmitoylethanolamide (PEA) can reduce the rundown of AChRs currents in ALS muscle, and if it can modify ALS patients' clinical and electrophysiological parameters.
    Detailed Description
    Outcome: Monitoring the efficacy and safety of PEA in the treatment of patients with ALS. Analysis of AChR currents and description of the composition of AChRs subunits in ALS muscles Design of the Study: A randomized controlled blinded study. Patients with sporadic ALS will receive riluzole alone or riluzole+PEA in order to investigate the clinical and electrophysiological effects of treatment. The expected number of enrolled patients will be 50. All patients satisfying the selection criteria will be randomized into two groups: a first group will be treated only with riluzole, the second group with riluzole associated with PEA (Normast 600 mg microgranular, 2 sachets/day). The randomization will be done stratifying patietns according to type of clinical onset (bulbar vs. spinal). The patients will be enrolled in the Department of Neurology and Psychiatry, University of Rome "Sapienza". The visits will be performed at 0 (randomization), 3 and 6 months. At each visit the ALS Functional Rating Scale-Revised (ALSFRS-R), the percentage of predicted forced vital capacity (FVC%), the Medical Research Council (MRC) score for muscle strength limited to the right upper limbs, and the compound muscle action potentials (CMAP) from right ulnar and phrenic nerves will be assessed. A muscle biopsy will be done at the end of the study. The obtained results will be compared with those observed in muscle samples from denervated (non-ALS) control patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Amyotrophic Lateral Sclerosis

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    50 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Riluzole
    Arm Type
    Active Comparator
    Arm Description
    Riluzole 50 mg twice daily in ALS patients
    Arm Title
    PEA plus Riluzole
    Arm Type
    Experimental
    Arm Description
    Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
    Intervention Type
    Drug
    Intervention Name(s)
    endocannabinoid palmitoylethanolamide (PEA)
    Other Intervention Name(s)
    PEA
    Intervention Description
    Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
    Intervention Type
    Drug
    Intervention Name(s)
    Riluzole
    Intervention Description
    Riluzole 50 mg twice daily
    Primary Outcome Measure Information:
    Title
    Changes from baseline in pulmonary capacity of ALS patients at 6 months.
    Description
    Changes of the percentage of predicted forced vital capacity (FVC %) will be measured
    Time Frame
    six months
    Secondary Outcome Measure Information:
    Title
    Changes in acetylcholine receptors (AChR) currents and Analysis of the composition of AChRs subunits in ALS muscles.
    Description
    Utilization of voltage-clamp intracellular recordings in oocytes transplanted with membranes from ALS muscles.
    Time Frame
    six months
    Title
    Changes from baseline in muscle strength of ALS patients at 6 months.
    Description
    Changes of the Medical Research Council (MRC) scale score will be measured
    Time Frame
    six months
    Title
    Changes from baseline in electrophysiological parameters of ALS patients at 6 months
    Description
    Changes of the compound muscle action potential (CMAP) amplitude of ulnar and phrenic nerves will be measured
    Time Frame
    six months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Diagnosis of ALS according to the El-Escorial criteria; Age> 18 years; ALS Functional Rating Scale-Revised (ALSFRS- r) score> 20; Forced Vital Capacity (FVC)> 30%; Treatment with Riluzole. Exclusion Criteria: Other diseases motor neurons; Experimental treatments in the previous three months; Pregnant or breast-feeding; Contraindications to the use of riluzole; Patients undergoing tracheostomy, enteral or parenteral supply; Severe psychiatric disorders.

    12. IPD Sharing Statement

    Learn more about this trial

    Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS

    We'll reach out to this number within 24 hrs